Skip to Main Content

Rep. Chris Collins, the New York lawmaker facing insider trading charges, was once the No. 2 shareholder in an Australian firm called Innate Immunotherapeutics. According to the company’s most recent disclosure, he’s no longer even in the top 20 shareholders.

What’s unclear is what happened to his shares.


Under law, members of Congress are required to publicly disclose their stock trades within 30 days. Yet there is no record of Collins having sold the bulk of his shares.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.